Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Nektar Therapeutics (NKTR) PT Lowered to $86 at Cowen
August 9, 2018 7:41 AM EDTCowen lowered its price target on Nektar Therapeutics (NASDAQ: NKTR) to $86.00 (from $101.00) while maintaining a Outperform rating.
... More